Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$1.32 USD
+0.07 (5.60%)
Updated Jun 21, 2024 03:59 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BRNS 1.32 +0.07(5.60%)
Will BRNS be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BRNS
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
Other News for BRNS
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics price target lowered by $3 at H.C. Wainwright, here's why
Barinthus Biotherapeutics price target lowered by $4 at Barclays, here's why
Barinthus Bio cuts 25% of staff amid pipeline shakeup